neuroblastoma
Oncology · 2025–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| eflornithine Post-maintenance treatment to prevent relapse in patients with high-risk neuroblastoma (HRNB) who are in remission after receiving multiagent, multimodality… | Mar 2025 | Recommended with restriction | 485 individuals Oncology Group · Solid Tumour Group · Healthcare Australasia · Neuroblastoma Australia · Rare Cancers Australia · Medical Oncology Group |
Who spoke
Oncology Group · Solid Tumour Group · Healthcare Australasia · Neuroblastoma Australia · Rare Cancers Australia · Medical Oncology Group
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| dinutuximab betaDinutuximab beta for treating neuroblastoma | TA538 | recommended restricted | 2018-08 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.